Shingles vaccine linked to 24% lower dementia risk — study scale makes it credible
A large observational study finds people vaccinated against shingles had a 24 percent lower risk of developing dementia — a substantial effect from an intervention that costs under £200 and is already recommended for adults over 50 in most high-income countries.
- Effect held across age groups and after adjusting for major confounders including cardiovascular health and prior healthcare access patterns
- Proposed mechanism: shingles triggers neuroinflammation; vaccination reduces viral reactivation risk and the inflammatory cascade thought to accelerate neurodegeneration
- Shingrix (recombinant zoster vaccine) provides stronger protection than Zostavax; the study cohort vaccine-type breakdown affects interpretation of absolute risk reduction